Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high.

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...